

## References

### X-5026-01

1. Zhao C, Zhang Y, Wang J. A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors. *AJNR Am J Neuroradiol*. Jun 2014;35(6):1058-1065. PMID 24029389.
2. Food and Drug Administration. Positron Emission Tomography (PET). 2016; <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm085783.htm>. Accessed August 16, 2019.
3. Riberich R. FDA-Approved PET Radiopharmaceuticals. <http://www.radiopharmaceuticals.info/pet-radiopharmaceuticals.html>. Accessed August 16, 2019.
4. Zhang H, Xing W, Kang Q, et al. Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis. *Tumour Biol*. May 2015;36(5):3209-3214. PMID 25809703.
5. Expert Panel on Urologic Imaging, van der Pol CB, Sahni VA, et al. ACR Appropriateness Criteria((R)) pretreatment staging of muscle-invasive bladder cancer. *J Am Coll Radiol*. May 2018;15(5S):S150-S159. PMID 29724418.
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 4.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/bladder.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf). Accessed August 16, 2019.
7. Liu F, Zhang Q, Zhu D, et al. Performance of positron emission tomography and positron emission tomography/computed tomography using fluorine-18-fluorodeoxyglucose for the diagnosis, staging, and recurrence assessment of bone sarcoma: a systematic review and meta-analysis. *Medicine (Baltimore)*. Sep 2015;94(36):e1462. PMID 26356700.
8. Treglia G, Salsano M, Stefanelli A, et al. Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. *Skeletal Radiol*. Mar 2012;41(3):249- 256. PMID 22072239.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 1.2020.

[https://www.nccn.org/professionals/physician\\_gls/pdf/bone.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf). Accessed August 16, 2019.

10. Dunet V, Pomoni A, Hottinger A, et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. *Neuro Oncol*. Mar 2016;18(3):426-434. PMID 26243791.

11. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. *J Nucl Med*. Feb 2012;53(2):207-214. PMID 22302961.

12. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography for Evaluating Breast Cancer. *Technol Eval Cent Assess*. 2003;18(14).

13. Deng SM, Zhang B, Wu YW, et al. Detection of glioma recurrence by (1)(1)C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. *Nucl Med Commun*. Aug 2013;34(8):758-766. PMID 23670103.

14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf). Accessed August 16, 2019.

15. Liang X, Yu J, Wen B, et al. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. *Clin Radiol*. Apr 2017;72(4):295-301. PMID 28139203.

16. Caldarella C, Treglia G, Giordano A. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. *Clin Breast Cancer*. Aug 2014;14(4):241-248. PMID 24472718.

17. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. *Med Sci Monit*. Mar 2007;13(3):RA37-46. PMID 17325645.

18. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography in Breast Cancer. *Technol Eval Cent Assess*. 2001;16(5).

19. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta- analysis. *Surg Oncol*. Jun 2013;22(2):139-143. PMID 23566435.
20. Rong J, Wang S, Ding Q, et al. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. *Surg Oncol*. Jun 2013;22(2):86-91. PMID 23726506.
21. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. *Breast Cancer Res Treat*. Mar 2005;90(2):105-112. PMID 15803356.
22. Xiao Y, Wang L, Jiang X, et al. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. *Nucl Med Commun*. Nov 2016;37(11):1180-1188. PMID 27428888.
23. Liu Q, Wang C, Li P, et al. The role of (18)F-FDG PET/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis. *Biomed Res Int*. Mar 2016;2016:3746232. PMID 26981529.
24. Sheikhabaei S, Trahan TJ, Xiao J, et al. FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies. *Oncologist*. Aug 2016;21(8):931-939. PMID 27401897.
25. Li H, Yao L, Jin P, et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. *Breast*. Aug 2018;40:106-115. PMID 29758503.
26. Cheng X, Li Y, Liu B, et al. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. *Acta Radiol*. Jul 2012;53(6):615-627. PMID 22734080.
27. Wang Y, Zhang C, Liu J, et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. *Breast Cancer Res Treat*. Jan 2012;131(2):357-369. PMID 21960111.
28. Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. *J Natl Compr Canc Netw*. May 2007;5(Suppl 1):S1-22; quiz S23-22. PMID 17509259.

29. Expert Panel on Breast Imaging, Moy L, Bailey L, et al. ACR Appropriateness Criteria((R)) Stage I Breast Cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. *J Am Coll Radiol*. May 2017;14(5S):S282-S292. PMID 28473085.
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed August 16, 2019.
31. Chu Y, Zheng A, Wang F, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. *Nucl Med Commun*. Feb 2014;35(2):144-150. PMID 24177043.
32. Ospina MB, Horton J, Seida J, et al. Technology Assessment Report : Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). Rockville, MD: Agency for Healthcare Research and Quality; 2008.
33. Yen TC, See LC, Chang TC, et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. *J Nucl Med*. Oct 2004;45(10):1632-1639. PMID 15471826.
34. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. *J Natl Compr Canc Netw*. Jun 2009;7(Suppl 2):S1-26. PMID 19555588.
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 4.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf). Accessed August 16, 2019.
36. Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. *Br J Radiol*. Dec 2017;90(1080):20170370. PMID 28972796.
37. Jones M, Hruby G, Solomon M, et al. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. *Ann Surg Oncol*. Oct 2015;22(11):3574-3581. PMID 25652048.

38. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Colorectal Cancer. *Technol Eval Cent Assess*. 1999;14(25).
39. Albertsson P, Alverbratt C, Liljegren A, et al. Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. Jun 2018;126:6-12. PMID 29759568.
40. Ye Y, Liu T, Lu L, et al. Pre-operative TNM staging of primary colorectal cancer by (18)F-FDG PET-CT or PET: a meta-analysis including 2283 patients. *Int J Clin Exp Med*. Feb 2015;8(11):21773-21785. PMID 26885142.
41. Li C, Lan X, Yuan H, et al. 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. *Ann Nucl Med*. Jun 2014;28(5):436-446. PMID 24623152.
42. Maffione AM, Chondrogiannis S, Capirci C, et al. Early prediction of response by (1)(8)F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. *Eur J Surg Oncol*. Oct 2014;40(10):1186-1194. PMID 25060221.
43. Memon S, Lynch AC, Akhurst T, et al. Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. *Ann Surg Oncol*. Oct 2014;21(11):3598-3607. PMID 24802909.
44. Gwynne S, Mukherjee S, Webster R, et al. Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review. *Clin Oncol (R Coll Radiol)*. Feb 2012;24(1):52-63. PMID 22035634.
45. Rymer B, Curtis NJ, Siddiqui MR, et al. FDG PET/CT can assess the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy: evidence from meta-analysis and systematic review. *Clin Nucl Med*. May 2016;41(5):371-375. PMID 26914561.
46. Yu T, Meng N, Chi D, et al. Value of (18)F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. *Cell Biochem Biophys*. Jun 2015;72(2):443-451. PMID 25737131.
47. Maffione AM, Marzola MC, Capirci C, et al. Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. *AJR Am J Roentgenol*. Jun 2015;204(6):1261- 1268. PMID 26001237.

48. Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. *Int J Colorectal Dis.* Aug 2013;28(8):1039-1047. PMID 23407908.
49. Sobhani I, Itti E, Luciani A, et al. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. *Ann Oncol.* Apr 1 2018;29(4):931-937. PMID 29365058.
50. Expert Panel on Gastrointestinal Imaging, Fowler KJ, Kaur H, et al. ACR Appropriateness Criteria((R)) pretreatment staging of colorectal cancer. *J Am Coll Radiol.* May 2017;14(5S):S234-S244. PMID 28473079.
51. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed August 16, 2019.
52. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). Accessed August 16, 2019.
53. Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, et al. High diagnostic value of 18F-FDG PET/CT in endometrial cancer: systematic review and meta-analysis of the literature. *J Nucl Med.* Jun 2016;57(6):879-885. PMID 26823564.
54. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf). Accessed August 16, 2019.
55. Kroese TE, Goense L, van Hillegersberg R, et al. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. *Dis Esophagus.* Jun 16 2018. PMID 29917073.
56. Cong L, Wang S, Gao T, et al. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis. *Jpn J Clin Oncol.* Dec 2016;46(12):1118-1126. PMID 27702836.

57. Goense L, van Rossum PS, Reitsma JB, et al. Diagnostic performance of (1)(8)F-FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. *J Nucl Med.* Jul 2015;56(7):995-1002. PMID 25952733.
58. Shi W, Wang W, Wang J, et al. Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer. *Surg Oncol.* Jun 2013;22(2):112-116. PMID 23478047.
59. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf). Accessed August 16, 2019.
60. Li P, Liu Q, Wang C, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. *Ann Nucl Med.* Apr 2016;30(3):179-187. PMID 26830546.
61. Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis. *Surg Oncol.* Sep 2013;22(3):162-166. PMID 23747134.
62. Wu LM, Hu JN, Hua J, et al. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. *J Gastroenterol Hepatol.* Mar 2012;27(3):472-480. PMID 21916986.
63. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf). Accessed August 16, 2019.
64. Chen WS, Li JJ, Hong L, et al. Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies. *Am J Transl Res.* Dec 2016;8(11):4532-4547. PMID 27904660.
65. Wei J, Pei S, Zhu X. Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis. *Oral Oncol.* Jan 2016;52:11-17. PMID 26547126.

66. Cheung PK, Chin RY, Eslick GD. Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT: systematic review and meta-analysis. *Otolaryngol Head Neck Surg*. Mar 2016;154(3):421-432. PMID 26715675.
67. Sheikhabaei S, Taghipour M, Ahmad R, et al. Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and meta-analysis. *AJR Am J Roentgenol*. Sep 2015;205(3):629-639. PMID 26295652.
68. Sheikhabaei S, Ahn SJ, Moriarty E, et al. Intratherapy or posttherapy FDG PET or FDG PET/CT for patients with head and neck cancer: a systematic review and meta-analysis of prognostic studies. *AJR Am J Roentgenol*. Nov 2015;205(5):1102-1113. PMID 26496559.
69. Rohde M, Dyrvig AK, Johansen J, et al. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. *Eur J Cancer*. Sep 2014;50(13):2271-2279. PMID 25011659.
70. Yi X, Fan M, Liu Y, et al. 18 FDG PET and PET-CT for the detection of bone metastases in patients with head and neck cancer. A meta-analysis. *J Med Imaging Radiat Oncol*. Dec 2013;57(6):674-679. PMID 24283555.
71. Gao S, Li S, Yang X, et al. 18FDG PET-CT for distant metastases in patients with recurrent head and neck cancer after definitive treatment. A meta-analysis. *Oral Oncol*. Mar 2014;50(3):163-167. PMID 24368204.
72. Helsen N, Van den Wyngaert T, Carp L, et al. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. *Eur J Nucl Med Mol Imaging*. Jun 2018;45(6):1063-1071. PMID 29478080.
73. Li Q, Zhang J, Cheng W, et al. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis. *Medicine (Baltimore)*. Sep 2017;96(37):e8084. PMID 28906411.
74. Lin J, Xie G, Liao G, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. *Oncotarget*. May 16 2017;8(20):33884-33896. PMID 27980228.



75. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Head and Neck Cancer. Technol Eval Cent Assess. 2000;15(4).

76. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf). Accessed August 16, 2019.

77. Barger RL, Jr., Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol. Feb 2012;19(2):153-158. PMID 22104289.

78. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography for Non-CNS Cancers. Technol Eval Cent Assess. 1997;12(3).

79. Brea TP, Ravina AR, Villamor JMC, et al. Use of magnetic resonance imaging for N-staging in patients with non- small cell lung cancer. a systematic review. Arch Bronconeumol. May 23 2018. PMID 29803524.

80. Ruilong Z, Daohai X, Li G, et al. Diagnostic value of 18F-FDG-PET/CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun. Jan 2017;38(1):67-75. PMID 27741214.

81. Li Y, Jin G, Su D. Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies. Oncotarget. May 30 2017;8(22):35743-35749. PMID 28415747.

82. He YQ, Gong HL, Deng YF, et al. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta- analysis. Acta Radiol. Apr 2014;55(3):309-317. PMID 24081215.

83. Li J, Xu W, Kong F, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. Sep 2013;22(3):151-155. PMID 23664848.

84. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 6.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed August 16, 2019.

85. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May 2013;143(5 Suppl):e211S-250S. PMID 23649440.
86. Lu YY, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. *Nucl Med Commun*. Jul 2014;35(7):697-703. PMID 24694775.
87. Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. *J Thorac Oncol*. Jun 2012;7(6):1015-1020. PMID 22534816.
88. Seidenfeld J, Samson DJ, Bonnell CJ, et al. Management of small cell lung cancer. *Evid Rep Technol Assess (Full Rep)*. Jul 2006(143):1-154.
89. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf). Accessed August 16, 2019.
90. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Lymphoma. *Technol Eval Cent Assess*. 1999;14(26).
91. Adams HJ, Kwee TC, de Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? *Ann Oncol*. May 2014;25(5):921-927. PMID 24351400.
92. Adams HJ, Kwee TC, de Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. Mar 2014;41(3):565- 574. PMID 24281821.
93. Adams HJ, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. *Eur J Radiol*. Nov 2016;85(11):1963-1970. PMID 27776647.
94. Adams HJ, Nievelstein RA, Kwee TC. Outcome of Hodgkin lymphoma patients with a posttreatment 18F-Fluoro- 2-Deoxy-d-Glucose positron emission tomography (FDG-PET)-negative residual mass: systematic review and meta-analysis. *Pediatr Hematol Oncol*. Nov 2015;32(8):515-524. PMID 26561044.

95. Adams HJ, Kwee TC. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis. *Eur J Haematol*. Apr 2017;98(4):337-347. PMID 27943422.
96. Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. *Ann Hematol*. Apr 2016;95(5):695-706. PMID 26931115.
97. Zhu D, Xu XL, Fang C, et al. Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis. *Int J Clin Exp Med*. Dec 2015;8(9):15340-15350. PMID 26629023.
98. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet*. Dec 23 2018;390(10114):2790-2802. PMID 29061295.
99. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/hodgkins.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf). Accessed August 16, 2019.
100. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non- Hodgkin's Lymphomas. Version 4.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf). Accessed August 16, 2019.
101. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hairy Cell Leukemia. Version 3.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/hairy\\_cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf). Accessed August 16, 2019.
102. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed August 16, 2019.
103. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas. Version 2.2019.

[https://www.nccn.org/professionals/physician\\_gls/pdf/t-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf). Accessed August 16, 2019.

104. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Melanoma. *Technol Eval Cent Assess*. 1999;14(27).

105. Rodriguez Rivera AM, Alabbas H, Ramjaun A, et al. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. *Surg Oncol*. Mar 2014;23(1):11-16. PMID 24556310.

106. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf). Accessed August 16, 2019.

107. Lu YY, Chen JH, Lin WY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. *Clin Nucl Med*. Sep 2012;37(9):833-837. PMID 22889770.

108. van Lammeren-Venema D, Regelink JC, Riphagen, II, et al. (1)(8)F-fluorodeoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. *Cancer*. Apr 15 2012;118(8):1971-1981. PMID 21887677.

109. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed August 16, 2019.

110. Barrio M, Czernin J, Fanti S, et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. *J Nucl Med*. May 2017;58(5):756- 761. PMID 28082438.

111. Deppen SA, Blume J, Bobbey AJ, et al. 68Ga-DOTATATE compared with 111In-DTPA-Octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. *J Nucl Med*. Jun 2016;57(6):872-878. PMID 26769864.

112. Treglia G, Castaldi P, Rindi G, et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and

gastroenteropancreatic neuroendocrine tumours: a meta-analysis. *Endocrine*. Aug 2012;42(1):80-87. PMID 22350660.

113. Treglia G, Cocciolillo F, de Waure C, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. *Eur J Nucl Med Mol Imaging*. Jul 2012;39(7):1144-1153. PMID 22358431.

114. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/neuroendocrine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf). Accessed August 16, 2019.

115. Xu B, Ma J, Jiang G, et al. Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta-analysis. *J Obstet Gynaecol Res*. Feb 2017;43(2):378-386. PMID 28150407.

116. Limei Z, Yong C, Yan X, et al. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. *Int J Gynecol Cancer*. May 2013;23(4):598-607. PMID 23502451.

117. Matchar DB, Kulasingam SL, Havrilesky L, et al. Positron Emission Testing for Six Cancers (Brain, Cervical, Small Cell Lung, Ovarian, Pancreatic and Testicular). Rockville, MD: Agency for Healthcare Research and Quality; 2004.

118. Expert Panel on Women's Imaging, Kang SK, Reinhold C, et al. ACR Appropriateness Criteria((R)) staging and follow-up of ovarian cancer. *J Am Coll Radiol*. May 2018;15(5S):S198-S207. PMID 29724422.

119. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed August 16, 2019.

120. Best LM, Rawji V, Pereira SP, et al. Imaging modalities for characterising focal pancreatic lesions. *Cochrane Database Syst Rev*. Apr 17 2017;4:CD010213. PMID 28415140.

121. Wang L, Dong P, Wang WG, et al. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. *Int J Surg*. Oct 2017;46:119-125. PMID 28890410.

122. Rijkers AP, Valkema R, Duivenvoorden HJ, et al. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. *Eur J Surg Oncol*. Jul 2014;40(7):794- 804. PMID 24755095.
123. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Pancreatic Cancer. *Technol Eval Cent Assess*. 1999;14(28).
124. Ghaneh P, Hanson R, Titman A, et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. *Health Technol Assess*. Feb 2018;22(7):1-114. PMID 29402376.
125. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 3.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf). Accessed August 16, 2019.
126. Sadeghi R, Gholami H, Zakavi SR, et al. Accuracy of 18F-FDG PET/CT for diagnosing inguinal lymph node involvement in penile squamous cell carcinoma: systematic review and meta-analysis of the literature. *Clin Nucl Med*. May 2012;37(5):436-441. PMID 22475891.
127. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Penile Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/penile.pdf](https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf). Accessed August 16, 2019.
128. Liu J, Chen Z, Wang T, et al. Influence of four radiotracers in PET/CT on diagnostic accuracy for prostate cancer: a bivariate random-effects meta-analysis. *Cell Physiol Biochem*. Jul 2016;39(2):467-480. PMID 27383216.
129. Ouyang Q, Duan Z, Lei J, et al. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis. *Tumour Biol*. Mar 2016;37(3):2999-3007. PMID 26415734.
130. Fanti S, Minozzi S, Castellucci P, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. *Eur J Nucl Med Mol Imaging*. Jan 2016;43(1):55-69. PMID 26450693.

131. von Eyben FE, Kairemo K. Meta-analysis of <sup>11</sup>C-choline and <sup>18</sup>F-choline PET/CT for management of patients with prostate cancer. *Nucl Med Commun.* Mar 2014;35(3):221-230. PMID 24240194.
132. Umbehrr MH, Muntener M, Hany T, et al. The role of <sup>11</sup>C-choline and <sup>18</sup>F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. *Eur Urol.* Jul 2013;64(1):106-117. PMID 23628493.
133. Mohsen B, Giorgio T, Rasoul ZS, et al. Application of (<sup>11</sup>) C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. *BJU Int.* Dec 2013;112(8):1062-1072. PMID 23937453.
134. Sandgren K, Westerlinck P, Jonsson JH, et al. Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy-a systematic review. *Eur Urol Focus.* Nov 10 2017. PMID 29133278.
135. Albisinni S, Aoun F, Marcelis Q, et al. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. *Minerva Urol Nefrol.* Aug 2018;70(4):347-360. PMID 29388415.
136. Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((<sup>18</sup>F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. *J Urol.* Mar 2017;197(3 Pt 1):676-683. PMID 27746282.
137. Andriole GL, Kostakoglu L, Chau A, et al. The Impact of Positron Emission Tomography with (<sup>18</sup>F)-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. *J Urol.* Sep 1 2018. PMID 30179618.
138. Akin-Akintayo OO, Jani AB, Odewole O, et al. Change in salvage radiotherapy management based on guidance with FACBC (Fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer. *Clin Nucl Med.* Jan 2017;42(1):e22-e28. PMID 27749412.
139. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. *Eur Urol.* Feb 2014;65(2):467-479. PMID 24321502.
140. Treglia G, Ceriani L, Sadeghi R, et al. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging

prostate cancer patients: a meta-analysis. *Clin Chem Lab Med*. May 2014;52(5):725-733. PMID 24310773.

141. Expert Panel on Urologic Imaging, Froemming AT, Verma S, et al. ACR Appropriateness Criteria((R)) post- treatment follow-up prostate cancer. *J Am Coll Radiol*. May 2018;15(5S):S132-S149. PMID 29724417.

142. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed August 16, 2019.

143. Eissa A, El Sherbiny A, Coelho RF, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of literature. *Minerva Urol Nefrol*. Apr 17 2018. PMID 29664244.

144. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta- analysis. *Eur Urol*. Dec 2016;70(6):926-937. PMID 27363387.

145. Ma H, Shen G, Liu B, et al. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. *Nucl Med Commun*. Feb 2017;38(2):156-163. PMID 27824726.

146. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2020. [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf). Accessed August 16, 2019.

147. Treglia G, Mirk P, Stefanelli A, et al. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. *Clin Imaging*. May-Jun 2012;36(3):167-175. PMID 22542374.

148. Ioannidis JPA, Lau J. FDG-PET for the Diagnosis and Management of Soft Tissue Sarcoma (Contract No. 290- 97-0019). Rockville, MD: Agency for Healthcare Research and Quality; 2002.

149. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Version 3.2019.



[https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf). Accessed August 16, 2019.

150. Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. *Eur J Radiol*. May 2005;54(2):284-288. PMID 15837411.

151. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/testicular.pdf](https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf). Accessed August 16, 2019.

152. Schutz F, Lautenschlager C, Lorenz K, et al. Positron emission tomography (PET) and PET/CT in thyroid cancer: a systematic review and meta-analysis. *Eur Thyroid J*. Jan 2018;7(1):13-20. PMID 29594049.

153. Haslerud T, Brauckhoff K, Reisaeter L, et al. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. *Acta Radiol*. Oct 2016;57(10):1193-1200. PMID 26163534.

154. Pace L, Klain M, Salvatore B, et al. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. *Clin Nucl Med*. Feb 2015;40(2):111-115. PMID 25546215.

155. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed August 16, 2019.

156. Cheng X, Bao L, Xu Z, et al. (1)(8)F-FDG-PET and (1)(8)F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. *J Med Imaging Radiat Oncol*. Apr 2012;56(2):136-142. PMID 22498184.

157. Burglin SA, Hess S, Hoiland-Carlsen PF, et al. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis. *Medicine (Baltimore)*. Apr 2017;96(16):e6713. PMID 28422888.

158. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography to Manage Patients with an Occult Primary

Carcinoma and Metastasis outside the Cervical Lymph Nodes. Technol Eval Cent Assess. 2002;17(14).

159. Centers for Medicare & Medicaid Services (CMS). Pub 100-03 National Coverage Determination (NCD) for Positron Emission TOMOGRAPHY (FDG) for Oncologic Conditions (220.6.17); <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=331&ncdver=4&NCAId=232&TAId=22&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&KeyWord=tomography&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAACAAAAAA&>. Accessed August 16, 2019.